Recursion Pharmaceuticals, Inc. RXRX Divestiture of businesses, net of cash transferred

Divestiture of businesses, net of cash transferred at other companies

BioCryst PharmaceuticalsBCRX

——

Revenue$6.5M-56.1%

Gross profit-$6.0M+15.0%

Operating income-$128.5M+32.8%

Net income-$117.5M+42.0%

EPS (diluted)-$0.22+56.0%

Cash & equivalents$665.2M+30.6%

Total debt$88.6M-24.6%

Total equity$1.0B+9.7%

Total assets$1.3B+2.6%

Operating cash flow-$81.1M+38.5%

CapEx$258.0K-85.9%

Free cash flow-$81.4M+39.2%

Market cap$1.71B-23.7%

Enterprise value$1.14B-39.8%

P/S25.8×-11.8×

Gross margin7.2%—

Operating margin-881.3%-66.8pp

Net margin-842.9%-92.4pp

FCF margin-490.7%-102pp

Return on equity-57.2%-14.4pp

Debt / equity0.1×0.0×

Current ratio5.5×+1.4×

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested.

The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Recursion Pharmaceuticals, Inc.'s divestiture of businesses, net of cash transferred?: Recursion Pharmaceuticals, Inc. (RXRX) reported divestiture of businesses, net of cash transferred of $0 in Q1 2026.
How has Recursion Pharmaceuticals, Inc.'s divestiture of businesses, net of cash transferred changed year-over-year?: Recursion Pharmaceuticals, Inc.'s divestiture of businesses, net of cash transferred increased by 100.0% year-over-year, from -$4.44M to $0.